User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Batm Advanced Communicat... Investors - BVC

Batm Advanced Communicat... Investors - BVC

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Batm Advanced Communications Ld BVC London Ordinary Share IL0010849045 ORD ILS0.01
  Price Change Price Change % Stock Price Last Trade
-0.50 -0.53% 94.40 16:35:07
Open Price Low Price High Price Close Price Previous Close
97.00 94.00 97.00 94.40 94.90
more quote information »
Industry Sector

Top Investor Posts

paulisi: Well it will certainly start up tomorrow.No idea why, it could be a number of reasons.Institutional investorLeaked RNSEtc
lsoc85: The AGM isn't until December; if they wish to pay a dividend sooner, they will have to convene a GM. Hopefully they do. It will provide investors with a strong indication of how the Board views the Company's prospects.
sandy789: Along with many investors who follow this platform i think that LSE fails to properly value the potential of tech company's. The shares are volatile due to the short termism speculative nature of the investors unlike the Nasdaq where investors appear to have a longer term perspective.
paulisi: They use proactive investors and have done for some time - BATM pay them to promote.They have also taken on a PR firm in London, Luther Pendragon, but I'm not convinced they have got the message across.They set up a Twitter account and it looks like they have revamped some of the websites.
fse: I agree with DocCash remarks ... BATM do regularly update Investors. The frustration is more about UK investors not understanding what BATM as a whole is about and lack of independent coverage. We have the Covid hype to deal with and the understanding that BATM medical solutions are going to be with us for the years ahead not just now. I would expect the medical side to continue growing the business and thats backed up with the situation on the ground. Telco systems is a totally different situation. The business was completely overhauled quite some years back to concentrate on finding software solutions to empower future Telecom Equipment. This is against the backdrop of the emergence of 5G, AI, NFV Telco systems are not winning contracts per se, rather they are entering into partnerships and licensing technology to major Telecom players. They are in advanced stages of POC's and are now starting to see these clients roll out upgrades. Zvi explained that Telco was generating revenue from placement of UCPE (white boxes) then revenue from licensing Cyber and NFVTime. Telco are already receiving revenue from these sources so the game has already begun. I thought the PCCW release was well calculated. They could not announce a large contract to supply X number of whatevers for X amount. Ergo they announce that PCCW Global one of their clients has finished all the POC stage, taken out whatever licenses they need and now incorporating these solutions into their own expansion/upgrade plans. Telco have developments with ARM and NXP and also Netwiz with Oracle and the list goes on. Having said all of that revenue increases in the months ahead are going to be hard to ignore and the likelihood of more announcements pretty much a certainty.
fse: Shares have been generally weak on TASE and firmer on LSE of late. Israel is heading into an election with no majority party again. I understand a lot of investors on TASE slimmed down holdings in this period. That may well be what the hold back is from. If so it will be over soon. FWIW
nellyb: emerard, simon thompson of the investors chronicle said on 18th January 2020 "a 2020 cash profit of 37 times to enterprise valuation is worth paying at this stage of its earnings upgrade cycle as this is a USD1bn (170p a share target) company IN THE MAKING." I doubt, after just a month that he will be head scratching too much.
pharmawotsit: It only helps one side of the argument when you see a headline like this from Alliance News yesterday: "Pandemic Lifts BATM Advanced Communications' BioMedical Unit Revenue " As we've seen, it's too easy to see this as a Covid-based stock if you're not interested in finding out about the company. It was good to hear yesterday that they've appointed an Investor Relations manager in the UK. Hopefully she'll try and highlight more of the gamut that is BATM.
car1pet: I think Marom needs to think very carefully about what he says at the AGM. For long term holders of this share it has been a continuous process of research and proof of concept in both telco and medical, we are at a point where Marom needs to realise that investors need a return on their investment/patience and an upwards trajectory of sales and profit. By all means carry on researching new products but the company has to focus on sales and profit. We can all admire his altruism and working for the greater good but he is running a business. He needs to separate his personal views and concentrate on giving investors a return on their investment. If I don't hear the right words I will invest elsewhere.
fse: This is now on Investors Chronicle Site for those who did not get the earlier scoop. Looks like he is referring to NFVTime. I have had a chance to read it over and would agree with his synopsis. .... heres the update "Investors have failed to grasp the significance of the latest contract wins from BATM Advanced Communications (BVC:115.5p), a provider of medical laboratory systems, diagnostic kits, cyber security and network solutions. The Israel-based technology group is now gaining significant traction in commercialising its valuable intellectual property, as I noted after BATM signed up its first tier 1 telecoms customer for its NFVTime virtual networking solution (‘Bull market pointers’, 1 September 2020). Operating on both Arm-based and Intel-based architectures, the cutting-edge technology enables network carriers to remotely deploy their own virtualised software-based networks. Analysts at house broker Shore Capital believe that revenue from this one customer alone could scale into a multi-million dollar recurring base over the next five years. NFV is critical in leveraging the benefits offered by 5G and the Internet of Things, so expect many more tier one customers to adopt the technology in due course. BATM’s medical laboratory systems business is firing on all cylinders, too, having just received an initial €4.3m (£3.9m) order for its Covid-19 Real-Time PCR diagnostic antigen test kits and instruments from a major global private laboratory group. BATM expects to receive “further significant orders from this customer during the current quarter and over the next 12 months”. In addition, the directors have updated investors on the progress being made on a raft of new diagnostic kits. BATM’s new multi-pathogen respiratory molecular diagnostics kit is in the final validation phase, with production and deliveries expected to commence shortly. In less than an hour the test can identify and differentiate between respiratory viruses including those that cause Covid-19, flu and the common cold. As the flu season approaches, this could be a game changer for medical authorities around the world. BATM is also commencing production of its new at-home test kit for flu, developed in partnership with Novamed, after being CE certified and validated. Finally, BATM has started to deliver its Covid-19 antigen kit, which has been upgraded to detect the spike (S) protein, thus providing more accurate results by identifying the virus even in those with a low viral load. This is important in preventing non- and pre-symptomatic individuals from unknowingly spreading the infection. It’s my strong view that revenues and profits from BATM’s high-growth segments will ramp up sharply in the coming years and in the process dramatically reduce BATM’s enterprise valuation to cash profit multiple of 42 times (based on 2020 estimates). The positive growth trends at work here also justify maintaining my buy recommendation even though the shares have already delivered a 540 per cent gain since I included them in my 2017 Bargain Shares portfolio. A return to this year’s 150p share price highs, and beyond, is not unrealistic. Buy.
ADVFN Advertorial
Your Recent History
Batm Advan..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210508 22:59:33